

Effects of high-flow oxygen therapy on patients with hypoxemia after extubation and predictors of reintubation: a retrospective study based on the MIMIC-IV database

Taotao Liu

Beijing Hospital

Qinyu Zhao

Australian National University

Bin Du (✉ dubin98@gmail.com)

Peking Union Medical College Hospital <https://orcid.org/0000-0001-6237-2895>

Research

Keywords: High-flow nasal cannula, Hypoxemia, Ventilator weaning, MIMIC

Posted Date: December 23rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-133541/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Purpose

To investigate the indications for high-flow nasal cannula oxygen (HFNC) therapy in patients with hypoxemia during ventilator weaning and to explore the predictors of reintubation when treatment fails.

Methods

Adult patients with hypoxemia weaning from mechanical ventilation were identified from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The patients were assigned to the treatment group or control group according to whether they were receiving HFNC or non-invasive ventilation (NIV) after extubation. The 28-day mortality and 28-day reintubation rates were compared between the two groups after Propensity score matching (PSM). The predictor for reintubation was formulated according to the risk factors with the XGBoost algorithm. The areas under the receiver operating characteristic curve (AUC) was calculated for reintubation prediction according to values at 4 hours after extubation, which was compared with the ratio of $\text{SpO}_2/\text{FiO}_2$ to respiratory rate (ROX index).

Results

A total of 524520 medical records were screened, and 801 patients with moderate or severe hypoxemia when undergoing mechanical ventilation weaning were included ($100 < \text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg), including 358 patients who received HFNC therapy after extubation in the treatment group. There were 315 patients with severe hypoxemia ($100 < \text{PaO}_2/\text{FiO}_2 \leq 200$ mmHg) before extubation, and 190 patients remained in the treatment group with median oxygenation index 166[157,180] mmHg after PSM. There were no significant differences in the 28-day reintubation rate or 28-day mortality between the two groups with moderate or severe hypoxemia (all $P > 0.05$). Then HR/SpO_2 was formulated as a predictor for 48-hour reintubation according to the important features predicting weaning failure. According to values at 4 hours after extubation, the AUC of HR/SpO_2 was 0.657, which was larger than that of ROX index (0.583). When the HR/SpO_2 reached 1.2 at 4 hours after extubation, the specificity for 48-hour reintubation prediction was 93%.

Conclusions

The treatment effect of HFNC therapy is not inferior to that of NIV, even on patients with oxygenation index from 160 to 180 mmHg when weaning from ventilator. HR/SpO_2 is more early and accurate in predicting HFNC failure than ROX index.

Introduction

High-flow nasal cannula (HFNC) treatment can offer continuously higher gas flow with better heat and humidity than conventional oxygen[1]. It is also popular because of its easy application and good tolerability[2]. Several high-quality studies have shown that the treatment effect of HFNC on patients with hypoxemia or patients after surgery is not inferior to that of noninvasive ventilation (NIV)[3–5]. However, both the indications for HFNC after early extubation in hypoxemic patients and the timing of reintubation when HFNC fails are unclear[6].

This retrospective study was designed based on the Medical Information Mart for Intensive Care IV (MIMIC-IV) database to investigate the indications for HFNC for patients with hypoxemia during ventilator weaning. A machine learning algorithm was used to explore the predictors of reintubation in these patients.

Methods

Patients

The patients were identified in the MIMIC-IV database from 2008 to 2019. The inclusion criteria were as follows: hypoxemia 4 hours before extubation ($100 < \text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg); over 18 years old; with or without hypercapnia; and received continuous or intermittent HFNC or NIV after extubation. The exclusion criteria were as follows: tracheotomy; accidental extubation; and received both HFNC and NIV after extubation.

Source of data and ethics approval

This retrospective study was conducted based on a large critical care database named Medical Information Mart for Intensive Care IV[7]. This database is an updated version of MIMIC-III with pre-existing institutional review board approval. A number of improvements have been made, including simplifying the structure, adding new data elements, and improving the usability of previous data elements. Currently, the MIMIC-IV contains comprehensive and high-quality data of patients admitted to intensive care units (ICUs) at the Beth Israel Deaconess Medical Center between 2008 and 2019 (inclusive). One author (QZ) obtained access to the database and was responsible for data extraction.

Study design

The treatment group received continuous or intermittent HFNC after extubation, and the control group received continuous or intermittent NIV after extubation.

The following data were recorded: age, sex, body mass index (BMI), comorbidities, simplified acute physiology scoring II (SAPS-II) score at ICU admission, duration of mechanical ventilation, reintubation rate, mortality, length of ICU stay, length of hospital stay and duration before reintubation.

Physiological parameters and arterial blood gas (ABG) from 4 hours before weaning to 48 hours after extubation were collected. Average values for each patient per four hours were assessed, and the median value and interquartile ranges (IQRs) in the two groups were plotted. The 28-day mortality of patients who received reintubation within 48 hours after extubation was compared with that of patients who received reintubation 48 hours after extubation.

Statistical analysis

Variables with normal distributions are presented as the means (SD) and were compared with independent samples *t* tests. Nonnormally distributed variables are expressed as medians and IQRs, which were compared with the Mann-Whitney U test. Categorical variables are described as percentages and were compared by using a chi-square test. A Kaplan-Meier curve was drawn to evaluate the time from extubation to reintubation, and a log-rank test was used to compare the differences in times between the two groups.

Patients with moderate ($200 < \text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg) to severe hypoxemia ($100 < \text{PaO}_2/\text{FiO}_2 \leq 200$ mmHg) were included for propensity score matching (PSM). Multivariate Imputation by Chained Equations was used to impute missing values, followed by the development of a multivariate logistic regression model to estimate the patient's propensity scores for HFNC treatment. One-to-one nearest neighbour matching with a caliper width of 0.1 was applied in the present study[8]. Statistical testing was performed to evaluate the effectiveness of PSM. The duration before reintubation, 28-day mortality, and 48-hour and 28-day reintubation rates were compared based on matched data. Additionally, subgroup analyses were separately performed on patients with moderate and severe hypoxemia. PSM was applied to each subgroup, and outcomes were compared based on the matched data.

The risk factors for reintubation were analysed by a machine learning algorithm. The extreme gradient boosting (XGBoost) model[9], an advanced ensemble learning algorithm, was developed to predict 48-hour reintubation risk based on the baseline variables. Feature importance was assessed by using the SHapley Additive exPlanations (SHAP) values[10]. Features were sorted according to the mean value of absolute SHAP values. Then, predictors were developed manually based on the baseline values of most important features. The areas under the receiver operating characteristic curve (AUCs) of the predictors to predict 48-hour reintubation were calculated and compared with the rapid shallow breathing index (RSBI) and the ratio of $\text{SpO}_2/\text{FiO}_2$ to respiratory rate (ROX index).

All statistical analyses were performed with R (version 3.6.1), and $p < 0.05$ was considered statistically significant.

Results

Propensity score adjusted and matched outcomes

A total of 524520 medical records were screened, including 20165 patients with planned extubation. Finally, 801 patients with moderate and severe hypoxemia when mechanical ventilation weaning was included ($100 < \text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg), and 358 patients received HFNC therapy after extubation in the treatment group. There were 233 patients remained in the treatment group with median oxygenation index 209[164,253] mmHg after PSM. There were no significant differences in age, sex, BMI, SPAS-II score, comorbidities, duration of mechanical ventilation or physiological parameters before weaning between the 2 groups (all $P > 0.05$).

There were no significant differences in the 28-day reintubation rate (4.29% vs. 5.15%, $P = 0.827$) or 28-day mortality (4.29% vs. 5.15%, $P = 0.827$) between the two groups. The 48-hour reintubation rate in the treatment group was lower than that in the control group (8.58% vs. 15.88%, $P = 0.024$).

There were 315 patients with severe hypoxemia ($100 < \text{PaO}_2/\text{FiO}_2 \leq 200$ mmHg) before extubation, and 190 patients remained in the treatment group with median oxygenation index 166[157,180] mmHg after PSM. There were no significant differences in the 48-hour reintubation rate, 28-day reintubation rate or 28-day mortality between the 2 groups (all $P > 0.05$).

There were 486 patients with moderate hypoxemia ($200 < \text{PaO}_2/\text{FiO}_2 \leq 300$ mmHg) before extubation, and 304 patients remained in the treatment group with median oxygenation index 238[214,267] mmHg after PSM. There were no significant differences in the 48-hour reintubation rate, 28-day reintubation rate or 28-day mortality between the 2 groups (all $P > 0.05$).

Both the length of stay in the ICU and in the hospital in the treatment group were longer than those in the control group (6.36 vs. 4.72 days, $P < 0.001$ and 12.62 vs. 10.93 days, $P = 0.001$). The duration before reintubation in the treatment group was longer than that in the control group (73.28 vs. 21.52 hours, $P = 0.001$). (Table 1 and Fig. 1)

The 28-day mortality of patients with reintubation 48 hours after extubation was not higher than that within 48 hours in either the treatment group or the control group (23.08% vs. 10.00%, $P = 0.206$ and 19.23% vs. 12.73%, $P = 0.509$). (Table 2)

Features and predictors of HFNC failure

The important features predicting weaning failure were PaO_2 , duration before extubation, heart rate, BMI, age, mean blood pressure, pH, SAPS-II, SpO_2 , tidal volume and respiratory rate (Fig. 2). Thus HR/PaO_2 and HR/SpO_2 were calculated manually based on the above important features. There was a significant difference of HR/SpO_2 at 4 hours after extubation between patients weaning failed and successfully (1.00 vs. 0.92, $P < 0.05$), and no significant difference of ROX index at the same time (7.38 vs. 7.29, $P > 0.05$). HR/SpO_2 increased more than 10% compared to baseline data in patients with failed HFNC treatment at

24 hours after extubation (1.06 vs. 0.93, $P < 0.05$) while there was no significant change in the ROX index at the same time (6.54 vs. 8.61, $P > 0.05$). (Table 3 and Fig. 3–4)

According to values at 4 hours before extubation, the AUCs of HR/ PaO_2 and HR/ SpO_2 were 0.640 and 0.618 for predicting 48-hour reintubation, respectively, which were larger than that of RSBI (AUC = 0.541) and ROX index (AUC = 0.551). According to values at 4 hours after extubation, the AUC of HR/ SpO_2 were 0.657 for predicting 48-hour reintubation, which were larger than that of ROX index (AUC = 0.583). The specificity reached 93% when the cut-off point of HR/ SpO_2 was 1.20 at 4 hours after extubation. (Table 4 and Fig. 5)

Table 1

The baseline data and prognosis of patients with hypoxemia of different severities in the two groups after

	1002/FiO ₂ ≤ 300				1002/FiO ₂ ≤ 200				2002/FiO ₂ ≤ 100
	n = 801				n = 315				n = 486
	After PSM n = 466	Treatment group n = 233	Control group n = 233	P value	After PSM n = 190	Treatment group n = 95	Control group n = 95	P value	After PSM n = 304
Age, median [Q1, Q3]	69.38[61.00, 77.59]	68.74[59.90, 77.81]	69.80[61.48, 76.32]	0.850	70.06[60.32, 78.09]	69.91[60.55, 77.58]	70.80[59.47, 78.50]	0.638	68.09[57.54, 75.49]
Male, n (%)	322(69.10)	158(67.81)	164(70.39)	0.616	126(66.32)	62(65.26)	64(67.37)	0.878	195(64.48)
BMI, mean (SD)	31.93(6.56)	32.04(6.60)	31.81(6.53)	0.708	33.85(6.47)	33.38(6.34)	34.34(6.61)	0.322	31.51(7.04)
Baseline disease									
Hypertension, n (%)	316(67.81)	157(67.38)	159(68.24)	0.921	123(64.74)	59(62.11)	64(67.37)	0.544	188(61.51)
Diabetes mellitus, n (%)	88(18.88)	47(20.17)	41(17.60)	0.554	30(15.79)	15(15.79)	15(15.79)	1.000	57(18.72)
COPD, n (%)	52(11.16)	29(12.45)	23(9.87)	0.462	17(8.95)	12(12.63)	5(5.26)	0.127	35(11.51)
Congestive heart failure, n (%)	133(28.54)	62(26.61)	71(30.47)	0.412	51(26.84)	20(21.05)	31(32.63)	0.102	79(25.98)
Myocardial infarction, n (%)	54(11.59)	28(12.02)	26(11.16)	0.885	25(13.16)	11(11.58)	14(14.74)	0.668	36(11.81)
Chronic kidney disease, n (%)	96(20.60)	51(21.89)	45(19.31)	0.567	35(18.42)	15(15.79)	20(21.05)	0.454	60(19.73)
Leukaemia, n (%)	3(0.64)	1(0.43)	2(0.86)	1.000	6(3.16)	2(2.11)	4(4.21)	0.682	3(0.99)
Strokes, n (%)	20(4.29)	11(4.72)	9(3.86)	0.819	5(2.63)	2(2.11)	3(3.16)	1.000	20(6.58)
Cancer, n (%)	48(10.30)	25(10.73)	23(9.87)	0.879	25(13.16)	16(16.84)	9(9.47)	0.198	33(10.84)
Liver disease, n (%)	32(6.87)	14(6.01)	18(7.73)	0.583	12(6.32)	9(9.47)	3(3.16)	0.136	32(10.53)
SAPS-II at admission, mean (SD)	42.99(12.44)	43.00(12.96)	42.97(11.92)	0.979	43.17(13.09)	43.42(13.60)	42.93(12.62)	0.795	42.61(12.54)
Duration before extubation, median [Q1,Q3], hours	20.77[6.89, 65.71]	22.00[7.32, 73.27]	19.50[6.12, 48.85]	0.136	21.73[6.68, 57.68]	24.00[6.73, 68.37]	20.47[6.76, 47.30]	0.304	19.78[6.11, 81.10]
Physiological variables before extubation 4 hours									
Heart rate, mean (SD)	83.15(13.84)	83.74(13.97)	82.55(13.72)	0.354	82.93(13.39)	82.72(12.30)	83.14(14.47)	0.832	83.94(13.84)
Respiratory rate, mean (SD)	18.99(3.95)	19.07(3.90)	18.91(4.00)	0.669	19.37(3.97)	19.40(4.06)	19.35(3.90)	0.938	18.81(3.95)
Tidal volume, mean (SD)	487.80(125.50)	493.81(127.26)	481.81(123.75)	0.337	504.61(134.40)	521.13(139.12)	487.07(127.73)	0.101	487.71(125.50)
MBP, mean (SD)	77.51(11.00)	77.80(11.62)	77.22(10.35)	0.570	77.91(10.51)	78.35(10.40)	77.46(10.65)	0.562	78.46(11.00)
pH, mean (SD)	7.40(0.05)	7.40(0.05)	7.39(0.05)	0.366	7.40(0.06)	7.40(0.06)	7.40(0.05)	0.358	7.39(0.05)
PaO ₂ , median [Q1, Q3]	100.00[84.00, 115.00]	97.75[83.00, 114.00]	101.50[86.00, 118.00]	0.208	84.42[76.25, 95.00]	84.50[78.75, 95.00]	84.33[76.00, 95.25]	0.924	109.00[84.00, 125.63]

	1002/FiO ₂ ≤ 300				1002/FiO ₂ ≤ 200				2002/FiO ₂ ≤ 100	
	n = 801				n = 315				n = 486	
PaCO ₂ , mean (SD)	41.01(6.96)	40.75(6.57)	41.26(7.34)	0.433	40.70[6.56]	40.61[6.12]	40.79[7.01]	0.852	41.08(6.96)	0.433
SpO ₂ , median [Q1, Q3]	97.50[95.83, 98.75]	97.25[95.80, 98.75]	97.50[96.00, 99.00]	0.397	96.06[94.68, 97.79]	95.75[94.50, 97.52]	96.50[94.90, 98.20]	0.152	98.00[96.00, 99.25]	0.397
PaO ₂ /FiO ₂ , median [Q1, Q3]	211.79[171.42, 253.23]	209.00[164.00, 253.62]	213.00[179.33, 253.06]	0.253	169.46[155.08, 182.83]	166.67[157.44, 180.60]	171.33[153.44, 187.56]	0.283	242.00[210.00, 270.23]	0.253
Reintubation 48 hours, n (%)	57(12.23)	20(8.58)	37(15.88)	0.024	24(12.63)	8(8.42)	16(16.84)	0.126	37(12.1)	0.024
Reintubation 28 days, n (%)	97(20.82)	46(19.74)	51(21.89)	0.648	39(20.53)	16(16.84)	23(24.21)	0.281	67(22.0)	0.648
Mortality 28 days, n (%)	22(4.72)	10(4.29)	12(5.15)	0.827	7(3.68)	3(3.16)	4(4.21)	1.000	21(6.91)	0.827
Duration before reintubation, median [Q1, Q3], hours	28.65[11.57, 90.78]	73.28[21.63, 124.15]	21.52[8.84, 56.85]	0.001	25.03[9.04, 113.43]	52.22[5.96, 163.10]	21.72[10.88, 66.22]	0.424	38.55[11.11, 111.62]	0.001
LOS in hospital, median [Q1, Q3]	11.54[7.18, 17.75]	12.62[7.65, 20.61]	10.93[6.83, 15.82]	0.001	11.87[7.65, 16.61]	12.80[7.79, 19.23]	11.28[7.48, 15.43]	0.102	12.01[7.19, 19.90]	0.001
LOS in ICU, median [Q1, Q3]	5.55[3.09, 11.14]	6.36[3.85, 13.59]	4.72[2.27, 9.70]	< 0.001	5.39[3.10, 10.93]	6.22[3.82, 12.69]	4.80[2.30, 9.39]	0.026	6.19[3.14, 13.14]	< 0.001

Table 2
The baseline data and prognosis of patients who received reintubation within 48 hours of and 48 hours after extubation in the two groups

	Treatment group				Control group			
	All reintubations n = 358	Within 48 h n = 40	48 h after n = 39	P value	All reintubations n = 443	Within 48 h n = 55	48 h after n = 26	P value
Age, median[Q1, Q3]	67.68[57.02, 78.00]	64.47[49.57, 77.97]	68.83[62.52, 77.59]	0.202	71.82[62.27, 78.93]	71.52[60.69, 78.69]	73.40[64.81, 78.74]	0.485
Male, n (%)	59(74.68)	31(77.50)	28(71.79)	0.746	48(59.26)	29(52.73)	19(73.08)	0.134
BMI, mean (SD)	29.65(5.87)	28.99(5.72)	30.38(6.02)	0.314	32.60(9.00)	31.12(8.34)	35.67(9.71)	0.051
Baseline disease								
Hypertension, n (%)	41(51.90)	18(45.00)	23(58.97)	0.309	54(66.67)	33(60.00)	21(80.77)	0.110
Diabetes mellitus, n (%)	12(15.19)	7(17.50)	5(12.82)	0.790	13(16.05)	7(12.73)	6(23.08)	0.331
COPD, n (%)	5(6.33)	3(7.50)	2(5.13)	1.000	9(11.11)	5(9.09)	4(15.38)	0.458
Congestive heart failure, n (%)	23(29.11)	10(25.00)	13(33.33)	0.570	29(35.80)	17(30.91)	12(46.15)	0.277
Myocardial infarction, n (%)	6(7.59)	4(10.00)	2(5.13)	0.675	14(17.28)	9(16.36)	5(19.23)	0.760
Chronic kidney disease, n (%)	17(21.52)	5(12.50)	12(30.77)	0.089	21(25.93)	10(18.18)	11(42.31)	0.041
Leukaemia, n (%)	1(1.27)	0	1(2.56)	0.494	2(2.47)	1(1.82)	1(3.85)	0.542
Strokes, n (%)	8(10.13)	1(2.50)	7(17.95)	0.029	6(7.41)	4(7.27)	2(7.69)	1.000
Cancer, n (%)	10(12.66)	6(15.00)	4(10.26)	0.737	16(19.75)	9(16.36)	7(26.92)	0.415
Liver disease, n (%)	12(15.19)	7(17.50)	5(12.82)	0.790	14(17.28)	8(14.55)	6(23.08)	0.360
SAPS-II at admission, mean (SD)	44.32(13.08)	43.30(10.86)	45.36(15.09)	0.490	47.20(13.72)	46.73(13.48)	48.19(14.45)	0.665
Duration before extubation, median [Q1,Q3], hours	61.50[20.33, 125.27]	53.92[15.14, 110.82]	67.35[22.86, 138.07]	0.364	38.90[20.25, 131.67]	40.83[23.53, 128.29]	28.46[17.63, 127.40]	0.413
Physiological variables before extubation 4 hours								
Heart rate, mean (SD)	87.28(15.55)	89.67(16.07)	84.84(14.80)	0.168	86.00(16.39)	87.03(14.03)	83.81(20.67)	0.476
Respiratory rate, mean (SD)	19.10(4.67)	19.41(4.09)	18.78(5.23)	0.556	19.73(4.17)	19.70(4.42)	19.79(3.64)	0.920
Tidal volume, mean (SD)	534.45(132.46)	527.92(146.70)	539.43(122.28)	0.734	454.31(111.36)	448.81(112.36)	466.35(110.87)	0.553
MBP, mean (SD)	79.62(12.93)	81.10(13.91)	78.10(11.82)	0.304	77.45(10.11)	77.61(10.55)	77.13(9.31)	0.836
pH, mean (SD)	7.41(0.07)	7.39(0.07)	7.42(0.06)	0.068	7.39(0.05)	7.39(0.06)	7.38(0.05)	0.831
PaO ₂ , median [Q1, Q3]	91.00[82.00, 107.00]	89.25[83.50, 104.62]	95.50[81.17, 110.50]	0.444	96.00[87.00, 108.00]	95.00[85.75, 106.25]	98.25[89.54, 115.00]	0.347
PaCO ₂ , mean (SD)	39.76(6.76)	39.52(6.60)	40.01(6.99)	0.751	44.79(10.47)	45.58(11.74)	43.10(7.01)	0.240
SpO ₂ , median [Q1, Q3]	97.00[95.54, 98.69]	96.50[95.00, 98.29]	97.25[96.38, 98.88]	0.088	97.25[95.50, 98.60]	97.80[95.75, 98.78]	96.50[95.56, 97.93]	0.172
PaO ₂ /FiO ₂ , median [Q1,Q3]	209.00[175.50, 248.62]	208.00[170.00, 229.86]	217.50[189.75, 254.30]	0.233	220.00[187.50, 252.52]	213.00[186.50, 254.32]	221.88[192.12, 249.65]	0.712
Mortality 28 days, n (%)	13(16.46)	4(10.00)	9(23.08)	0.206	12(14.81)	7(12.73)	5(19.23)	0.509

Table 3
Changes in physiological parameters in patients with successful or failed weaning in the HFNC treatment

	Failed n = 40					Successful n = 318		
	4 hours before extubation	4 hours after extubation	8–12 hours later	20–24 hours later	36–40 hours	4 hours before reintubation	4 hours before extubation	4 hours after extubation
Heart rate, mean (SD)	†89.67(16.07)	†94.62 (17.57)	†94.26 (18.59)	*†99.78 (14.64)	*†115.05 (9.92)	*99.18 (18.88)	83.01(13.42)	*87.65 (14.48)
Respiratory rate, mean (SD)	19.41(4.09)	*†22.83 (4.29)	*22.64 (5.31)	*†24.40 (5.69)	26.88 (8.09)	*24.47 (4.81)	19.31(4.29)	*21.21 (4.75)
Tidal volume, mean (SD)	527.92(146.70)	-	-	-	-	-	504.81(126.12)	-
MBP, mean (SD)	81.10(13.91)	80.82 (15.61)	83.41 (14.24)	81.46 (14.29)	81.91 (12.14)	*83.97 (14.58)	78.34(11.79)	79.95 (12.62)
pH, mean (SD)	7.39(0.07)	7.37 (0.12)	7.40 (0.08)	7.36 (0.10)	7.42 (0.08)	7.38 (0.10)	7.40(0.06)	7.41 (0.07)
PaO ₂ , median [Q1, Q3]	89.25[83.50, 104.62]	91.50 [74.38,119.00]	*75.50 [64.50,95.00]	*81.00 [72.50,82.75]	75.50 [68.75,82.25]	*76.75 [66.75,98.50]	92.50[80.00, 110.00]	*83.00 [71.00,99.00]
PaCO ₂ , mean (SD)	39.52(6.60)	41.78 (7.62)	39.61 (6.56)	39.00 (9.94)	47.50 (4.95)	40.09 (9.12)	40.00(6.83)	39.65 (7.36)
SpO ₂ , median [Q1, Q3]	96.50[95.00, 98.29]	*95.12 [93.94,95.88]	*95.38 [93.44,96.43]	*94.25 [93.66,95.62]	95.00 [94.50,96.25]	*93.27 [91.69,95.29]	97.00[95.00, 98.50]	*95.00 [93.75,96.59]
PaO ₂ /FiO ₂ , median [Q1,Q3]	208.00[170.00, 229.88]	*151.61 [133.75,171.50]	*129.00 [100.83,130.00]	*95.30 [85.99,111.55]	*†75.50 [68.75,82.25]	*98.84 [79.38,147.03]	201.29[163.20, 238.35]	*137.75 [102.12,175.50]
ROX Index	†8.61 [7.57,9.45]	7.38 [5.27,9.49]	6.95 [5.25,8.75]	6.54 [4.82,9.33]	5.32 [3.93, 8.12]	*3.54 (0.43)	11.63 [9.22,13.51]	*7.29 [6.33,8.62]
RSBI	40.35[30.71, 54.80]	-	-	-	-	*49.88 [40.31,55.09]	39.22[29.87, 50.51]	-
HR/PaO ₂	†0.97(0.22)	1.05 (0.37)	1.17 (0.34)	*1.25 (0.27)	1.64 (0.49)	*1.25 (0.45)	0.89(0.27)	*1.07 (0.33)
HR/SpO ₂	†0.93(0.16)	†1.00 (0.19)	0.99 (0.19)	*†1.06 (0.16)	*†1.22 (0.10)	*1.06 (0.20)	0.86(0.14)	*0.92 (0.15)
† P < 0.05 vs value of patients with successful weaning, * P < 0.05 vs value at baseline								

Table 4
Predicting power of HFNC failure by HR/PaO₂, HR/SpO₂, RSBI and the ROX index at 4 hours before and after extubation

	AUC(95% CI)	P	Cutoff value	Youden Index	Sensitivity	Specificity	PPV	NPV
4 hours before extubation								
HR/PaO ₂	0.640 [0.584, 0.694]	P < 0.01	0.829	0.263	0.733	0.530	0.159	0.943
HR/SpO ₂	0.618 [0.551, 0.683]	P < 0.01	0.830	0.215	0.733	0.481	0.146	0.937
RSBI	0.541 [0.467, 0.607]	P < 0.01	48.4	0.120	0.413	0.707	0.146	0.909
ROX index	0.551 [0.488, 0.610]	P < 0.01	0.107	0.168	0.640	0.528	0.141	0.924
4 hours after extubation								
HR/SpO ₂	0.657 [0.571, 0.724]	P < 0.01	1.203	0.330	0.400	0.930	0.462	0.911
ROX index	0.583 [0.519, 0.629]	P < 0.01	6.376	0.020	0.800	0.220	0.133	0.880

Discussion

In our study, more than 500,000 medical records from 2008 to 2019 were selected from MIMIC-IV, and 801 patients with moderate to severe hypoxemia during mechanical ventilation weaning who received HFNC or NIV therapy were finally included. There were no significant differences in primary outcomes, including the 28-day reintubation rate and 28-day mortality, between the HFNC treatment group and the control group after PSM. Consistent results were confirmed in

patients with moderate and severe hypoxemia. HFNCs can provide constant airflow and oxygen concentration with a small amount of positive end-expiratory pressure[11–13]. Therefore, the therapeutic effect of HFNC is better than that of conventional oxygen, including nasal catheters and facemasks[6, 14, 15]. Most research designs in recent years have been noninferior studies of HFNC and NIV, but the specific indication of hypoxemia is not clear. HFNC is noninferior to NIV for preventing postextubation respiratory failure in patients at high risk of reintubation or resolving acute respiratory failure in patients who receive cardiothoracic surgery. In these studies, the mean oxygenation index of those patients with moderate hypoxemia was nearly 200 mmHg[4, 5]. Our study found that the effect of HFNC therapy was not inferior to that of NIV, even for severely hypoxemic patients with median oxygenation index of 170 mmHg.

The reintubation rate for ICU patients weaning from mechanical ventilation is approximately 10%[16], but it can reach 20% in patients at high risk when HFNC fails, and the timing of reintubation is mostly concentrated within 48 hours after weaning[4, 5], which is consistent with our results. Therefore, patients who received reintubation within 48 hours were regarded as having treatment failure in the HFNC treatment group, and we tried to predict reintubation within 48 hours after extubation[17].

The longer length of ICU stay followed a longer duration before reintubation with the use of HFNC compared with NIV, which is in contrast to previous findings[6]. However, the mortality of patients who received reintubation within 48 hours was not higher than that of patients who received reintubation 48 hours after extubation in the HFNC group. In contrast to our findings, a previous study found that delayed intubation in patients with hypoxemia who received HFNC therapy might increase mortality[18]. The different results may be caused by different experimental designs and cohort sample sizes.

Although RSBI is routinely used as a clinical predictor of extubation failure, the threshold value for RSBI less than 105 had poor predictability for weaning success when measured at baseline during the spontaneous breathing trial, and it can be significantly affected by the level of ventilator support[19–21]. Moreover, the tidal volume is not routinely monitored after weaning. In patients with acute hypoxemic respiratory failure, the respiratory rate was a predictor of intubation under standard oxygen but not under high-flow nasal cannula oxygen or noninvasive ventilation[22]. Studies have shown that effective therapy for HFNC can decrease the work of breathing and reduce the respiratory rate of patients[23, 24]. Therefore, we think that the RSBI composed of tidal volume and respiratory rate is not a good predictor for reintubation with HFNC failure. ROX index is defined as the ratio of $\text{SpO}_2/\text{FiO}_2$ to respiratory rate[25], which needs further verification as a predictor of HFNC failure. At present, a simple and clear predictor for whether patients need early reintubation after weaning is still needed, and the timing of switching to invasive ventilator therapy is also not clear when HFNC fails[26, 27].

The risk factors for reintubation within 48 hours after extubation were analysed by the XGBoost model in our study. According to the results of the machine algorithm, heart rate and PaO_2 are more important features than respiratory rate. In another study, heart rate was also used to modify the ROX index as a predictor of HFNC failure treatment[28]. And SpO_2 , instead of tidal volume, is a physiological parameter monitored routinely. Therefore, we propose to use HR/PaO_2 or HR/SpO_2 as predictors of reintubation.

As serial measurements of the RSBI and ROX index could more accurately predict successful weaning from mechanical ventilators[19, 29], we also observed the dynamic changes in these two indexes during extubation. The AUCs of HR/SpO_2 according to values at 4 hours before and after extubation to predict reintubation were larger than those of ROX index. The HR/SpO_2 of patients with failed HFNC treatment was higher than that of patients with successful HFNC treatment within 4 hours after weaning, but there was no significant difference of ROX index at the same time. Both HR/SpO_2 and ROX index changed more than 10% compared to baseline data in patients with failed HFNC treatment at 24 hours. The specificity of predicting HFNC treatment failure reached 93% when the threshold value of HR/SpO_2 was 1.20 at 4 hours after extubation, which was larger than that of ROX index. Therefore, HR/SpO_2 may be a more sensitive and accurate predictor than ROX index for reintubation when HFNC treatment fails.

Limitations

Our study is a retrospective study based on the MIMIC-IV database. The daily time of HFNC and NIV treatment in the treatment group and the control group was not extracted, which would have an impact on the treatment effect. Although the sample size was not small and propensity score matching ensured low heterogeneity in the included patients, the results of this study need to be verified by multicentre, large-sample prospective studies.

Conclusions

The treatment effect of HFNC therapy is not inferior to that of NIV, even on patients with oxygenation index from 160 to 180 mmHg when weaning from ventilator. HR/SpO_2 is more early and accurate in predicting HFNC failure than ROX index within 48 hours after extubation.

Abbreviations

HFNC: high-flow nasal cannula; NIV: noninvasive ventilation; MIMIC-IV: the Medical Information Mart for Intensive Care IV; ICUs: intensive care units; BMI: body mass index; SAPS-II: the simplified acute physiology scoring II; ABG: arterial blood gas; IQR: interquartile range; PSM: propensity score matching; XGBoost: the extreme gradient boosting; SHAP: the Shapley additive explanations; AUC: the area under the receiver operating characteristic curve; RSBI: the rapid shallow breathing index; ROX index: the ratio of $\text{SpO}_2/\text{FiO}_2$ to respiratory rate.

Declarations

Acknowledgments

None

Funding

None

Availability of data and materials

The MIMIC-IV data were available on the project website at <https://mimic-iv.mit.edu/>.

Authors' contributions

Taotao Liu conceived the idea, interpreted the results and drafted the manuscript. Qinyu Zhao extracted the data, performed the analysis, and helped to revise the manuscript. Bin Du helped to frame the idea of the study and helped to revise the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was an analysis of two third-party anonymized publicly available databases with pre-existing institutional review board (IRB) approval.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Nishimura M: **High-flow nasal cannula oxygen therapy in adults.** *Journal of Intensive Care* 2015, **3**(1):15.
2. Lenglet H, Sztrymf B, Leroy C, Brun P, Dreyfuss D, Ricard J-D: **Humidified High Flow Nasal Oxygen During Respiratory Failure in the Emergency Department: Feasibility and Efficacy.** *Respiratory care* 2012, **57**.
3. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottureau A *et al*: **High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure.** *The New England journal of medicine* 2015, **372**(23):2185-2196.
4. Hernandez G, Vaquero, Colinas L, Cuenca R, Arenas P, Canabal A, Sanchez S, Rodriguez M, Villascclaras A, Fernandez R *et al*: **Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients A Randomized Clinical Trial Supplemental content.** *JAMA The Journal of the American Medical Association* 2016, **316**.
5. Stéphan F, Barrucand B, Petit P, Rézaiguia-Delclaux S, Médard A, Delannoy B, Cosserant B, Flicoteaux G, Imbert A, Pilorge C *et al*: **High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial.** *Jama* 2015, **313**(23):2331-2339.
6. Granton D, Chaudhuri D, Wang D, Einav S, Helviz Y, Mauri T, Mancebo J, Frat J-P, Jog S, Hernandez G *et al*: **High-Flow Nasal Cannula Compared With Conventional Oxygen Therapy or Noninvasive Ventilation Immediately Postextubation: A Systematic Review and Meta-Analysis.** *Critical care medicine* 2020, **48**(11):e1129-e1136.
7. Johnson A, Bulgarelli L, Pollard T, Horng S, Celi LA, Mark R: **MIMIC-IV (version 0.4).** *PhysioNet* 2020.
8. Leite W: **Practical Propensity Score Methods Using R;** 2016.
9. Chen T, Guestrin C: **XGBoost: A Scalable Tree Boosting System.** In: *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining.* San Francisco, California, USA: Association for Computing Machinery; 2016: 785–794.
10. Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Himmelfarb J, Bansal N, Lee S-I: **From local explanations to global understanding with explainable AI for trees.** *Nature Machine Intelligence* 2020, **2**(1):56-67.
11. Groves N, Tobin A: **High flow nasal oxygen generates positive airway pressure in adult volunteers.** *Australian Critical Care* 2007, **20**(4):126-131.
12. Parke R, McGuinness S, Eccleston M: **Nasal high-flow therapy delivers low level positive airway pressure.** *British journal of anaesthesia* 2009, **103**(6):886-890.
13. Chikata Y, Onodera M, Oto J, Nishimura M: **FIO2 in an Adult Model Simulating High-Flow Nasal Cannula Therapy.** *Respir Care* 2017, **62**(2):193-198.
14. Hernández G, Vaquero C, González P, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Colinas L, Cuenca R, Fernández R: **Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial.** *Jama* 2016, **315**(13):1354-1361.
15. Wang Y, Huang D, Ni Y, Liang Z: **High-Flow Nasal Cannula vs Conventional Oxygen Therapy for Postcardiothoracic Surgery.** *Respiratory Care* 2020:respcare.07595.
16. Miltiades AN, Gershengorn HB, Hua M, Kramer AA, Li G, Wunsch H: **Cumulative Probability and Time to Reintubation in U.S. ICUs.** *Critical care medicine* 2017, **45**(5):835-842.
17. Beduneau G, Pham T, Schortgen F, Piquilloud L, Zogheib E, Jonas M, Grelon F, Runge I, Grangé S, Barberet G *et al*: **Epidemiology of Weaning Outcome According to a New Definition. The WIND Study.** *American journal of respiratory and critical care medicine* 2016, **195**.
18. Kang BJ, Koh Y, Lim C-M, Huh JW, Baek S, Han M, Seo H-S, Suh HJ, Seo GJ, Kim EY *et al*: **Failure of high-flow nasal cannula therapy may delay intubation and increase mortality.** *Intensive care medicine* 2015, **41**(4):623-632.

19. Krieger BP, Isber J, Breitenbucher A, Throop G, Ershowsky P: **Serial Measurements of the Rapid-Shallow-Breathing Index as a Predictor of Weaning Outcome in Elderly Medical Patients.** *Chest* 1997, **112**(4):1029-1034.
20. Patel K, Ganatra K, Bates J, Young M: **Variation in the rapid shallow breathing index associated with common measurement techniques and conditions.** *Respiratory care* 2009, **54**:1462-1466.
21. Frutos-Vivar F, Ferguson ND, Esteban A, Epstein SK, Arabi Y, Apezteguía C, González M, Hill NS, Nava S, D'Empaire G *et al*: **Risk Factors for Extubation Failure in Patients Following a Successful Spontaneous Breathing Trial.** *Chest* 2006, **130**(6):1664-1671.
22. Frat JP, Ragot S, Coudroy R, Constantin j-m, Girault C, Prat G, Boulain T, Demoule A, Ricard J-D, Razazi K *et al*: **Predictors of Intubation in Patients With Acute Hypoxemic Respiratory Failure Treated With a Noninvasive Oxygenation Strategy.** *Critical care medicine* 2017, **46**:1.
23. Corley A, Caruana LR, Barnett AG, Tronstad O, Fraser JF: **Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients.** *British journal of anaesthesia* 2011, **107**(6):998-1004.
24. Wagstaff TAJ, Soni N: **Performance of six types of oxygen delivery devices at varying respiratory rates*.** *Anaesthesia* 2007, **62**(5):492-503.
25. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernandez G, García-de-Acilu M, Frat JP, Masclans J, Ricard J-D: **An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High Flow Therapy.** *American journal of respiratory and critical care medicine* 2018, **199**.
26. McConville JF, Kress JP: **Weaning patients from the ventilator.** *The New England journal of medicine* 2012, **367**(23):2233-2239.
27. Saugel B, Rakette P, Hapfelmeier A, Schultheiss C, Phillip V, Thies P, Treiber M, Einwächter H, von Werder A, Pfab R *et al*: **Prediction of extubation failure in medical intensive care unit patients.** *Journal of critical care* 2012, **27**(6):571-577.
28. Goh K, Chai HZ, Ong T, Sewa D, Phua G, Tan Q: **Early prediction of high flow nasal cannula therapy outcomes using a modified ROX index incorporating heart rate.** *Journal of Intensive Care* 2020, **8**.
29. Spinelli E, Roca O, Mauri T: **Dynamic assessment of the ROX index during nasal high flow for early identification of non-responders.** *Journal of critical care* 2020, **58**:130-131.

Figures




Figure 1




Figure 2
Important features of the machine learning XGBoost model in reintubation prediction




Figure 3

Changes in HR/PaO2, HR/SpO2 and the ROX index in patients who received re-intubation within 48 hours in the two groups




Figure 4

Values of HR/SpO2 and ROX index at 4 and 24 hours after extubation in two groups




Figure 5

The ROC curves of HR/PaO₂, HR/SpO₂, ROX index, and RSBI for 48-hour reintubation prediction in the HFNC treatment group

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [STROBEchecklistv4combined.docx](#)